Login Register Cart 0
Generic placeholder image

Current Molecular Medicine

Editor-in-Chief

ISSN (Print): 1566-5240
ISSN (Online): 1875-5666

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in Chinese
Research Article

Untargeted Metabolomic Analyses of Body Fluids to Differentiate TBI DOC and NTBI DOC

Author(s): Xiaoping Xiao, Long Xu, Hezhen Lu, Xiaoyan Liu, Haidan Sun, Zhengguang Guo, Jiameng Sun, Feng Qi, Xia Niu, Aiwei Wang, Qianqian Ge, Yutong Zhuang, Xiaoli Geng, Xueling Chen, Ying Lan*, Jianghong He* and Wei Sun*

Volume 24, Issue 9, 2024

Published on: 04 October, 2023

Page: [1183 - 1193] Pages: 11

DOI: 10.2174/0115665240249826230928104512

Price: $65

Abstract

Objective: To investigate the metabolomic differences between Traumatic brain injury (TBI) disorder of consciousness (DOC) patients and non-traumatic brain injury (NTBI) DOC patients by using cerebrospinal fluid (CSF), serum and urine samples beneficial to understand the pathological mechanism differences between the two etiologies, provide potential clues for the subsequent treatment and prognosis, and investigate the metabolome differences and similarities between TBI and NTBI among three different body fluids.

Methods: In total, 24 TBI DOC subjects and 29 NTBI DOC subjects were enrolled. CSF, serum and urine samples from TBI DOC and NTBI DOC patients were collected and analyzed by performing UPLC-MS. The statistical methods and pathway analyses were applied to discover potential biomarkers and altered metabolic functions.

Results: When comparing TBI DOC and NTBI DOC, 36, 31 and 52 differential metabolites were obtained in CSF, serum and urine, respectively. The functional analysis of differential metabolites obtained in CSF, serum and urine were all related to amino acid metabolism. Except for amino acid metabolism, metabolic biomarkers in CSF, serum and urine mainly focus on central function, cognitive function, necrosis and apoptosis and neurological function, respectively. In CSF, the highest AUC was 0.864 (Isoproturon) and 0.816 (Proline betaine). Then, the AUC of NFurfurylformamide in serum was 0.941, while the AUC of Dihydronepetalactone and Doxepin N-oxide glucuronide were 1.0 in urine.

Conclusion: CSF, serum and urine metabolomic analyses could differentiate TBI DOC from NTBI DOC and functional analyses showed a metabolic change difference between TBI DOC and NTBI DOC.

Keywords: DOC, TBI, NTBI, metabolomic, biomarker, necrosis.

« Previous
[1]
Adukauskienė D, Budrytė B, Karpec D. Coma: Etiology, diagnosis, and treatment. Medicina (Kaunas) 2008; 44(10): 812-9.
[http://dx.doi.org/10.3390/medicina44100102] [PMID: 19001840]
[2]
Gross T, Schüepp M, Attenberger C, Pargger H, Amsler F. Outcome in polytraumatized patients with and without brain injury. Acta Anaesthesiol Scand 2012; 56(9): 1163-74.
[http://dx.doi.org/10.1111/j.1399-6576.2012.02724.x] [PMID: 22735047]
[3]
Multi-Society Task Force on PVS. Medical aspects of the persistent vegetative state (1). N Engl J Med 1994; 330(21): 1499-508.
[http://dx.doi.org/10.1056/NEJM199405263302107] [PMID: 7818633]
[4]
Multi-Society Task Force on PVS. Medical aspects of the persistent vegetative state (2). N Engl J Med 1994; 330(22): 1572-9.
[http://dx.doi.org/10.1056/NEJM199406023302206] [PMID: 8177248]
[5]
Lewis GD, Wei R, Liu E, et al. Metabolite profiling of blood from individuals undergoing planned myocardial infarction reveals early markers of myocardial injury. J Clin Invest 2008; 118(10): 3503-12.
[http://dx.doi.org/10.1172/JCI35111] [PMID: 18769631]
[6]
Khamis MM, Adamko DJ, El-Aneed A. Mass spectrometric based approaches in urine metabolomics and biomarker discovery. Mass Spectrom Rev 2017; 36(2): 115-34.
[http://dx.doi.org/10.1002/mas.21455] [PMID: 25881008]
[7]
Dandekar SP, Karekar AK. Cancer metabolomics: A tool of clinical utility for early diagnosis of gynaecological cancers. Indian J Med Res 2021; 154(6): 787-96.
[http://dx.doi.org/10.4103/ijmr.IJMR_239_19] [PMID: 35662083]
[8]
Bujak R, Struck-Lewicka W, Markuszewski MJ, Kaliszan R. Metabolomics for laboratory diagnostics. J Pharm Biomed Anal 2015; 113: 108-20.
[http://dx.doi.org/10.1016/j.jpba.2014.12.017] [PMID: 25577715]
[9]
Liu X, Cheng X, Liu X, et al. Investigation of the urinary metabolic variations and the application in bladder cancer biomarker discovery. Int J Cancer 2018; 143(2): 408-18.
[http://dx.doi.org/10.1002/ijc.31323] [PMID: 29451296]
[10]
Eiden M, Christinat N, Chakrabarti A, et al. Discovery and validation of temporal patterns involved in human brain ketometabolism in cerebral microdialysis fluids of traumatic brain injury patients. EBioMedicine 2019; 44: 607-17.
[http://dx.doi.org/10.1016/j.ebiom.2019.05.054] [PMID: 31202815]
[11]
Thomas I, Dickens AM, Posti JP, et al. Serum metabolome associated with severity of acute traumatic brain injury. Nat Commun 2022; 13(1): 2545.
[http://dx.doi.org/10.1038/s41467-022-30227-5] [PMID: 35538079]
[12]
Orešič M, Posti JP, Kamstrup-Nielsen MH, et al. Human serum metabolites associate with severity and patient outcomes in traumatic brain injury. EBioMedicine 2016; 12: 118-26.
[http://dx.doi.org/10.1016/j.ebiom.2016.07.015] [PMID: 27665050]
[13]
Maudsley AA, Govind V, Saigal G, Gold SG, Harris L, Sheriff S. Longitudinal mr spectroscopy shows altered metabolism in traumatic brain injury. J Neuroimaging 2017; 27(6): 562-9.
[http://dx.doi.org/10.1111/jon.12463] [PMID: 28736910]
[14]
Banoei MM, Casault C, Metwaly SM, Winston BW. Metabolomics and biomarker discovery in traumatic brain injury. J Neurotrauma 2018; 35(16): 1831-48.
[http://dx.doi.org/10.1089/neu.2017.5326] [PMID: 29587568]
[15]
Posti JP, Dickens AM, Orešič M, Hyötyläinen T, Tenovuo O. Metabolomics profiling as a diagnostic tool in severe traumatic brain injury. Front Neurol 2017; 8: 398.
[http://dx.doi.org/10.3389/fneur.2017.00398] [PMID: 28868043]
[16]
Fiandaca MS, Mapstone M, Mahmoodi A, et al. Plasma metabolomic biomarkers accurately classify acute mild traumatic brain injury from controls. PLoS One 2018; 13(4): e0195318.
[http://dx.doi.org/10.1371/journal.pone.0195318] [PMID: 29677216]
[17]
Montaner J, Ramiro L, Simats A, et al. Multilevel omics for the discovery of biomarkers and therapeutic targets for stroke. Nat Rev Neurol 2020; 16(5): 247-64.
[http://dx.doi.org/10.1038/s41582-020-0350-6] [PMID: 32322099]
[18]
Shin TH, Lee DY, Basith S, et al. Metabolome changes in cerebral ischemia. Cells 2020; 9(7): 1630.
[http://dx.doi.org/10.3390/cells9071630] [PMID: 32645907]
[19]
Wolahan SM, Hirt D, Braas D, Glenn TC. Role of metabolomics in traumatic brain injury research. Neurosurg Clin N Am 2016; 27(4): 465-72.
[http://dx.doi.org/10.1016/j.nec.2016.05.006] [PMID: 27637396]
[20]
Kimberly WT, Wang Y, Pham L, Furie KL, Gerszten RE. Metabolite profiling identifies a branched chain amino acid signature in acute cardioembolic stroke. Stroke 2013; 44(5): 1389-95.
[http://dx.doi.org/10.1161/STROKEAHA.111.000397] [PMID: 23520238]
[21]
Inoue Y, Shiozaki T, Tasaki O, et al. Changes in cerebral blood flow from the acute to the chronic phase of severe head injury. J Neurotrauma 2005; 22(12): 1411-8.
[http://dx.doi.org/10.1089/neu.2005.22.1411] [PMID: 16379579]
[22]
Overgaard J, Tweed WA. Cerebral circulation after head injury. J Neurosurg 1976; 45(3): 292-300.
[http://dx.doi.org/10.3171/jns.1976.45.3.0292] [PMID: 948015]
[23]
Nakae R. Coagulation and fibrinolytic disorder. No Shinkei Geka 2021; 49(5): 946-53. [Coagulation and Fibrinolytic Disorder].
[PMID: 34615754]
[24]
Buonacera A, Stancanelli B, Malatino L. Stroke and hypertension: An appraisal from pathophysiology to clinical practice. Curr Vasc Pharmacol 2018; 17(1): 72-84.
[http://dx.doi.org/10.2174/1570161115666171116151051] [PMID: 29149815]
[25]
Jahng GH, Oh J, Lee DW, et al. Glutamine and glutamate complex, as measured by functional magnetic resonance spectroscopy, alters during face-name association task in patients with mild cognitive impairment and alzheimer’s disease. J Alzheimers Dis 2016; 52(1): 145-59.
[http://dx.doi.org/10.3233/JAD-150877] [PMID: 27060946]
[26]
Lever M, Slow S. The clinical significance of betaine, an osmolyte with a key role in methyl group metabolism. Clin Biochem 2010; 43(9): 732-44.
[http://dx.doi.org/10.1016/j.clinbiochem.2010.03.009] [PMID: 20346934]
[27]
Zhong C, Miao M, Che B, et al. Plasma choline and betaine and risks of cardiovascular events and recurrent stroke after ischemic stroke. Am J Clin Nutr 2021; 114(4): 1351-9.
[http://dx.doi.org/10.1093/ajcn/nqab199] [PMID: 34159355]
[28]
Dixon KJ. Pathophysiology of traumatic brain injury. Phys Med Rehabil Clin N Am 2017; 28(2): 215-25.
[http://dx.doi.org/10.1016/j.pmr.2016.12.001] [PMID: 28390509]
[29]
Choi DW. Ischemia-induced neuronal apoptosis. Curr Opin Neurobiol 1996; 6(5): 667-72.
[http://dx.doi.org/10.1016/S0959-4388(96)80101-2] [PMID: 8937832]
[30]
Yun DH, Jeon ES, Sung SM, Ryu SH, Kim JH. Lysophosphatidylcholine suppresses apoptosis and induces neurite outgrowth in PC12 cells through activation of phospholipase D2. Exp Mol Med 2006; 38(4): 375-84.
[http://dx.doi.org/10.1038/emm.2006.44] [PMID: 16953116]
[31]
Sun Y, Lee JH, Kim NH, et al. Lysophosphatidylcholine-induced apoptosis in H19-7 hippocampal progenitor cells is enhanced by the upregulation of Fas Ligand. Biochim Biophys Acta Mol Cell Biol Lipids 2009; 1791(1): 61-8.
[http://dx.doi.org/10.1016/j.bbalip.2008.09.007] [PMID: 19007912]
[32]
Simpson BN, Kim M, Chuang YF, et al. Blood metabolite markers of cognitive performance and brain function in aging. J Cereb Blood Flow Metab 2016; 36(7): 1212-23.
[http://dx.doi.org/10.1177/0271678X15611678] [PMID: 26661209]
[33]
Li M, Zhou L, Sun X, et al. Dopamine, a co-regulatory component, bridges the central nervous system and the immune system. Biomed Pharmacother 2022; 145: 112458.
[http://dx.doi.org/10.1016/j.biopha.2021.112458] [PMID: 34847478]
[34]
Klein MO, Battagello DS, Cardoso AR, Hauser DN, Bittencourt JC, Correa RG. Dopamine: Functions, signaling, and association with neurological diseases. Cell Mol Neurobiol 2019; 39(1): 31-59.
[http://dx.doi.org/10.1007/s10571-018-0632-3] [PMID: 30446950]
[35]
Warren N, O’Gorman C, Lehn A, Siskind D. Dopamine dysregulation syndrome in Parkinson’s disease: a systematic review of published cases. J Neurol Neurosurg Psychiatry 2017; 88(12): 1060-4.
[http://dx.doi.org/10.1136/jnnp-2017-315985] [PMID: 29018160]
[36]
Segura-Aguilar J, Paris I, Muñoz P, Ferrari E, Zecca L, Zucca FA. Protective and toxic roles of dopamine in Parkinson’s disease. J Neurochem 2014; 129(6): 898-915.
[http://dx.doi.org/10.1111/jnc.12686] [PMID: 24548101]
[37]
Eisenhofer G, Kopin IJ, Goldstein DS. Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacol Rev 2004; 56(3): 331-49.
[http://dx.doi.org/10.1124/pr.56.3.1] [PMID: 15317907]
[38]
Chen B, Tong X, Zhang X, et al. Sulfation modification of dopamine in brain regulates aggregative behavior of animals. Natl Sci Rev 2022; 9(4): nwab163.
[http://dx.doi.org/10.1093/nsr/nwab163] [PMID: 35530433]
[39]
Suominen T, Piepponen TP, Kostiainen R, Kostiainen R. Permeation of dopamine sulfate through the blood-brain barrier. PLoS One 2015; 10(7): e0133904.
[http://dx.doi.org/10.1371/journal.pone.0133904] [PMID: 26207745]
[40]
Osier ND, Ziari M, Puccio AM, et al. Elevated cerebrospinal fluid concentrations of N-acetylaspartate correlate with poor outcome in a pilot study of severe brain trauma. Brain Inj 2019; 33(10): 1364-71.
[http://dx.doi.org/10.1080/02699052.2019.1641743] [PMID: 31305157]
[41]
Elting JW, Sulter GA, Langedijk M, Luijckx GJ, Teelken AW, De Keyser J. N-acetylaspartate: Serum marker of reperfusion in ischemic stroke. J Stroke Cerebrovasc Dis 2004; 13(6): 254-8.
[http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2004.08.002] [PMID: 17903983]

Rights & Permissions Print Cite
Article Metrics
21
4
Wayfinder Image
© 2024 Bentham Science Publishers | Privacy Policy